Biogen Inc.
Biogen Inc. (0R1B.L) Financial Performance & Income Statement Overview
Explore the financials of Biogen Inc. (0R1B.L), including yearly and quarterly data on income, cash flow, and balance sheets.
Biogen Inc. (0R1B.L) Income Statement & Financial Overview
Analyze Biogen Inc.’s 0R1B.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $2.65B | $2.43B | $2.45B | $2.47B |
| Cost of Revenue | $0.00 | $629.30M | $583.50M | $638.70M |
| Gross Profit | $0.00 | $1.80B | $1.87B | $1.83B |
| Gross Profit Ratio | $0.00 | $0.74 | $0.76 | $0.74 |
| R&D Expenses | $399.00M | $434.10M | $532.30M | $542.70M |
| SG&A Expenses | $583.80M | $572.50M | $680.00M | $588.40M |
| Operating Expenses | $982.80M | $1.18B | $1.42B | $1.33B |
| Total Costs & Expenses | $1.90B | $1.81B | $2.004B | $1.97B |
| Interest Income | $0.00 | $23.90M | $18.50M | $11.60M |
| Interest Expense | $0.00 | $60.00M | $60.00M | $59.80M |
| Depreciation & Amortization | $0.00 | $183.20M | $184.00M | $182.80M |
| EBITDA | $0.00 | $554.40M | $535.50M | $693.60M |
| EBITDA Ratio | $0.00 | $0.23 | $0.22 | $0.28 |
| Operating Income | $0.00 | $625.20M | $450.60M | $496.40M |
| Operating Income Ratio | $0.00 | $0.26 | $0.18 | $0.20 |
| Other Income/Expenses (Net) | $0.00 | -$314.00M | -$159.10M | -$45.40M |
| Income Before Tax | $744.00M | $311.20M | $291.50M | $451.00M |
| Income Before Tax Ratio | $0.28 | $0.13 | $0.12 | $0.18 |
| Income Tax Expense | $109.20M | $70.70M | $24.80M | $62.50M |
| Net Income | $634.80M | $240.50M | $266.70M | $388.50M |
| Net Income Ratio | $0.24 | $0.10 | $0.11 | $0.16 |
| EPS | $146.50 | $1.65 | $1.83 | $2.67 |
| Diluted EPS | $146.70 | $1.65 | $1.83 | $2.66 |
| Weighted Avg Shares Outstanding | $0.00 | $145.90M | $145.70M | $145.70M |
| Weighted Avg Shares Outstanding (Diluted) | $0.00 | $145.90M | $146.10M | $145.90M |
Over the past four quarters, Biogen Inc. demonstrated steady revenue growth, increasing from $2.47B in Q3 2024 to $2.65B in Q2 2025. Operating income reached $0.00 in Q2 2025, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $0.00, reflecting operational efficiency. Net income rose to $634.80M, with EPS at $146.50. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan